Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

23.80USD
20 Jan 2017
Change (% chg)

$-0.08 (-0.34%)
Prev Close
$23.88
Open
$23.93
Day's High
$24.04
Day's Low
$23.75
Volume
1,812,267
Avg. Vol
8,788,701
52-wk High
$24.79
52-wk Low
$15.67

Latest Key Developments (Source: Significant Developments)

Boston Scientific to buy Neovasc advanced biological tissue capabilities
Friday, 2 Dec 2016 07:00am EST 

Boston Scientific Corp : Boston Scientific announces agreement to acquire Neovasc Advanced Biological tissue capabilities . Boston Scientific - acquisition expected to be immaterial to Boston Scientific earnings per share (EPS) in 2016 and 2017 on an adjusted and GAAP basis .Boston Scientific Corp - Neovasc advanced biological tissue capabilities will be integrated into Boston Scientific structural heart business.  Full Article

Boston Scientific acquires tissue resection device from Distal Access
Tuesday, 15 Nov 2016 06:44am EST 

Boston Scientific Corp : Boston Scientific Corp- specific terms of transaction were not disclosed . Boston Scientific acquires resectr™ tissue resection device from distal access, llc . Boston Scientific Corp - deal is immaterial to earnings per share (eps) in 2016 and 2017 on an adjusted and gaap basis .Boston Scientific acquires resectr™ tissue resection device from distal access, llc.  Full Article

Boston Scientific reports acquisition of the Lumenr tissue retractor system
Thursday, 3 Nov 2016 06:30am EDT 

Boston Scientific Corp : Boston Scientific announces acquisition of the lumenr™ tissue retractor system . Acquisition of lumenr is immaterial to earnings per share (EPS) in 2016 and 2017 on an adjusted and gaap basis . Specific terms of transaction were not disclosed. . Will integrate lumenr system into its endoscopy development program .Boston scientific announces acquisition of the lumenr™ tissue retractor system.  Full Article

EndoChoice holdings agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances
Tuesday, 27 Sep 2016 09:27am EDT 

Endochoice Holdings Inc :Agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances.  Full Article

Boston Scientific to acquire EndoChoice for $8.00/share
Tuesday, 27 Sep 2016 06:30am EDT 

Boston Scientific Corp : To evaluate strategic options with respect to FUSE colonoscope, and expects to provide further clarity at/around time of deal closing . Boston Scientific to acquire EndoChoice . Boston scientific will launch a tender offer for all EndoChoice outstanding shares at a cash price of $8.00 per share . Acquisition is expected to be breakeven to Boston Scientific adjusted earnings per share in 2017, and accretive thereafter . Total equity value is approximately $210 million and transaction is expected to close in Q4 of 2016 . Says upon completion of transaction, EndoChoice will become part of Boston Scientific endoscopy business . Transaction is expected to be less accretive on a GAAP basis, due to amortization expense and transaction and integration costs in 2017 .Total equity value is approximately $210 million.  Full Article

Paulson & Co raises share stake in Valeant, Facebook - SEC filing
Monday, 15 Aug 2016 04:35pm EDT 

Paulson & Co: Takes share stake in Johnson & Johnson - SEC filing . Ups share stake in Valeant Pharmaceuticals International Inc by 43.6 pct to 19.1 mln shares - SEC filing . Takes share stake of 72,800 shares in Fedex Corp . Takes share stake in VMWare Inc of 2 million class A common shares . Ups share stake in Facebook Inc to 144,400 class A shares from 44,000 class A shares . Ups share stake in Boston Scientific Corp by 27.0 percent to 94,000 shares . Cuts share stake in T-Mobile US Inc by 93.3 percent to 979,900 shares - SEC filing . Cuts share stake in Perrigo Co PLC to 12,500 shares from 2.6 million shares .Change in holdings are as of June 30, 2016 and compared with the previous quarter ended as of March 31, 2016.  Full Article

Boston Scientific gets FDA approval for Emblem MRI system
Tuesday, 9 Aug 2016 07:00am EDT 

Boston Scientific Corp : Announces U.S. FDA approval of EMBLEM™ MRI S-ICD System .FDA approval for magnetic resonance (MR) conditional labeling for all previously implanted Emblem S-ICD systems.  Full Article

Boston Scientific enters into stipulation of settled issues with IRS
Wednesday, 20 Jul 2016 06:33am EDT 

Boston Scientific Corp : Does not expect to recognize any additional charges related to resolution . Boston Scientific Corp says expects to remit all tax and interest payments resulting from this settlement to IRS in next 12 to 24 months . Settled issues with IRS intended to resolve all disputes related to previously disclosed transfer pricing issues for guidant corp . Says entered into a stipulation of settled issues with Internal Revenue Service . Company does not expect to change its 2016 estimated annual effective tax rate as a result of resolution - SEC filing . If settlement is finalized, will make net tax payments to IRS of about $275 million to resolve both controversy before tax court .Will make net tax payments to irs of about $275 million to also resolve the transfer pricing issues before irs appeals.  Full Article

Boston Scientific reaffirms 2016 revenue guidance
Thursday, 9 Jun 2016 06:16am EDT 

Boston Scientific Corp : Reaffirms FY 2016 revenue guidance provided on April 27, for estimated revenue to be in a range of $8.075 to $8.225 billion . Now estimates FY income (GAAP) to be in a range of $0.59 to $0.65 per share . Continues to estimate FY adjusted earnings in a range of $1.06 to $1.10 per share .Company continues to estimate sales for Q2 of $2.01-$2.06 billion; estimates income on GAAP basis to be $0.12-$0.15/share.  Full Article

Boston scientific announces restructuring program and headcount reductions
Wednesday, 8 Jun 2016 06:30pm EDT 

Boston Scientific Estimates That Program To Reduce Gross Annual Pre : Expects some employee attrition and targeted headcount reductions to result from these restructuring initiatives . Company expects to reinvest a substantial portion of savings in strategic growth initiatives . Tax operating expenses by approximately $115 million to $150 million by end of 2020 . Program implementation is anticipated to result in total pre-tax charges of approximately $175 million to $225 million . Program implementation is anticipated to result in total pre-tax charges of approximately $175 million to $225 million . Several program activities will be initiated immediately,all activities are expected to be substantially completed by end of 2018 . Several program activities will be initiated immediately and all activities are expected to be substantially completed by end of 2018 . Boston scientific corp says anticipates that its overall employee base will remain relatively unchanged upon completion of restructuring program . Expects to reinvest a substantial portion of savings in "strategic growth" initiatives . Expects some employee attrition and targeted headcount reductions to result from these restructuring initiatives .Term growth and innovation.  Full Article

Photo

Bracco, Guerbet looking for partners for Bayer radiology bids: sources

FRANKFURT Italian healthcare group Bracco is working on a potential bid for the radiology supplies unit that Germany's Bayer AG is considering selling, people close to the matter said.